



ADULT MEDICATION GUIDELINE

ENALAPRIL

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the **Disclaimer**.

Quick Links

DoseAdministrationMonitoringPregnancy and Breastfeeding

Restrictions

Formulary: Unrestricted

Medication Class

Antihypertensive agent

Angiotensin Converting Enzyme (ACE) Inhibitors

Presentation

Form: Tablet: 5mg, 10mg

Storage

Store at room temperature, below 25°C. Protect from light and moisture.

Dose

Indication 1: Post-partum hypertension

Oral:

5mg daily, increased at intervals of 1 to 2 weeks up to 10-40mg daily in one or two doses.

Administration

Oral

With or without food

Monitoring

Blood pressure

Renal function and electrolytes prior to therapy then review as needed

Pregnancy

1st Trimester: Contraindicated
2nd Trimester: Contraindicated
3rd Trimester: Contraindicated

Breastfeeding

Considered safe to use

For more information, please contact **KEMH Obstetric Medicines Information Service**.

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

KEMH Clinical Guideline: O&G: <u>Hypertension in Pregnancy: Medical Management</u>

KEMH Clinical Guideline: O&G: Cardiac disease

References

Australian Medicines Handbook. Enalapril. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 March 22]. Available from: https://amhonline.amh.net.au/

The Royal Women's Hospital. Enalapril. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2022 March 22]. Available from: https://thewomenspbmg.org.au/

MIMS Australia. Enalapril. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2022 March 22]. Available from: https://www.mimsonline.com.au

Keywords	Enalapril, hypertension, blood pressure, ACE inhibitor					
Document Owner:	Chief Pharmacist					
Author/ Reviewer	KEMH Pharmacy Department					
Version Info:	4.0					
Date First Issued:	01/01/2015	Last Reviewed:	01/05/2022		Review Date:	01/05/2025
Endorsed by:	Medicines and Therapeutics Committee				Date:	05/07/2022
NSQHS Standards	Std 1: Clinical Governance					
Applicable:	Std 4: Medication Safety					
Printed or personally saved electronic copies of this document are considered uncontrolled.						
Access the current version from WNHS HealthPoint.						

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.